Clinical Trials Browser

Phase 2 × Hodgkin Disease × mocetinostat × Clear all

NCT00358982 2015-07-03

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2 Terminated

Hodgkin Disease, Recurrence

NCT00543582 2015-07-01

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Phase 2 Terminated

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell